Search Mailing List Archives

Limit search to: Subject & Body Subject Author
Sort by: Reverse Sort
Limit to: All This Week Last Week This Month Last Month
Select Date Range     through    

[bioontology-support] Case Study on the Development of rFVIIa Analogue by Novo Nordisk A/S

Immunogenicity & Immunotoxicity Conference igit at
Tue Oct 22 21:27:32 PDT 2013

rFVIIa Analogue Case Study by Novo Nordisk A/S 
2nd Immunogenicity & Immunotoxicity Conference | January 29-31, 2014 | San Diego, CA 
If you can't view this page, please visit: JMEL-25246 

Dear Colleague,

Kasper Lamberth, Head of the Immunogenicity Prediction and Tolerance Department at Novo Nordisk A/S, will give a featured presentation on "Using Immunogenicity Prediction Tools to Identify CD4+ T-cell Epitopes in an rFVIIa Analogue Giving Rise to ADAs?" at the 2nd  Immunogenicity and Immunotoxicity Conference to be held on January 29-31, 2014 in San Diego, CA . Dr. Lamberth will discuss the development of an rFVIIa analogue (Vatreptacog alfa) which was recently discontinued due to the development of ADAs in a phase 3 trial. The talk will present data from in silico and ex vivo immunogenicity prediction tools on full length molecules and on peptides with different length.

Make sure to register by November 29th to take advantage of the 20% early registration discount! The Immunogenicity and Immunotoxicity Conference will provide guests with a better understanding of the ongoing research for tools to mitigate risks associated with the immunogenicity of therapeutic proteins. Attendees will get an up-to-date understanding of the mechanisms and consequences of protein aggregation and insights on how to prosecute state-of-the-art assessment of the clinical immunogenicity of therapeutic proteins.

The conference will feature following sessions:
Immunotoxicity Evaluation of Novel Drug Candidates 
Risk Assessment and Management 
Immunogenicity Assessment for Biosimilars 
Protein Aggregation Biological Activity and Immunogenicity 
ADC Immunogenicity 
Clinical Relevance of Immunogenicity 
Immunogenicity and Drug Hypersensitivity 
Immunogenicity Prediction, Causes, Mitigation and Strategies 
Register with the early registration discount and save up to $350.

Submit an abstract by December 29, 2013 for an oral presentation opportunity at the conference. Selected presentations will be based on quality of abstract and availability. Presentation slots fill up fast so please submit your abstract soon. 
The 2nd Immunogenicity & Immunotoxicity Conference is part of the Novel Immunotherapeutics Summit 2014. The Summit includes 300 anticipated attendees, over 15 sponsors and exhibitors as well as 3 additional conferences: 
12th Cytokines & Inflammation 
6th Immunotherapeutics and Immunomonitoring 
Inaugural Innate Immunity 

Register for the summit today and receive access to all 4 conferences and receive 20% off the registration price. 
Group Discount: Bring 3 people for the price of 2 with discount code rcdvb.
For business development & exhibiting opportunities, contact Amber Kempf, 626-256-6405 x110 or spex at 


Please visit to view our upcoming conferences.
This advertisement is sent to support at from GTC, 635 W. Foothill Blvd, Monrovia, CA 91016. If you prefer not to receive further messages from this sender, please forward this email to remove at or use the following link to unsubscribe 

-------------- next part --------------
An HTML attachment was scrubbed...
URL: <>

More information about the bioontology-support mailing list